Eli Lilly Shares Gain After Results Beat Estimates, Obesity Drug Data
(Reuters) – Eli Lilly and Co on Thursday posted quarterly results that beat Wall Street estimates and said its experimental obesity drug met the main goal in a late-stage study, sending shares of the drugmaker up 4%. Tirzepatide showed up to 22.5% weight loss in adults with obesity in the study, with the trial also…
